Asia-Pacific Journal of Clinical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Exosomal tetraspanins as regulators of cancer progression and metastasis and novel diagnostic markers
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 25, 2018 Category: Cancer & Oncology Source Type: research

Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 24, 2018 Category: Cancer & Oncology Source Type: research

Chemotherapy in patients with unresected pancreatic cancer in Australia: A population ‐based study of uptake and survival
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 23, 2018 Category: Cancer & Oncology Source Type: research

Patients ’ experiences and preferences for opt‐in models and health professional involvement in biobanking consent: A cross‐sectional survey of Australian cancer outpatients
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 23, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology, Ahead of Print. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 23, 2018 Category: Cancer & Oncology Source Type: research

Issue Information
Asia-Pacific Journal of Clinical Oncology,Volume 14, Issue 2, Page e1-e2, April 2018. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 13, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology,Volume 14, Issue 2, Page e1-e2, April 2018. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 13, 2018 Category: Cancer & Oncology Source Type: research

Issue Information
(Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 13, 2018 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research

The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage Ⅰ–Ⅲ colorectal cancer
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 12, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology, Ahead of Print. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 12, 2018 Category: Cancer & Oncology Source Type: research

Do FHIT gene alterations play a role in human solid tumors?
Asia-Pacific Journal of Clinical Oncology, EarlyView. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 8, 2018 Category: Cancer & Oncology Source Type: research

---
Asia-Pacific Journal of Clinical Oncology, Ahead of Print. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 8, 2018 Category: Cancer & Oncology Source Type: research

Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite
ConclusionThe EPIC questionnaire was successfully translated into Chinese and was culturally adapted. The resultant Chinese version has high reliability and validity and will be an important tool for research on quality of life in the Chinese population. (Source: Asia-Pacific Journal of Clinical Oncology)
Source: Asia-Pacific Journal of Clinical Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Tsz Kin Lee, Darren M.C. Poon, Anthony C.F. Ng, Terrence Ho, Savitri Singh ‐Carlson, Michel Joffres, Gurpreet Oshan, Jagbir Kohli, Winkle Kwan Tags: SUPPLEMENT ARTICLE Source Type: research

Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months ’ survival
Abstract Non–small cell lung cancers (NSCLC) harboring the uncommon epidermal growth factor receptor (EGFR) exon 20 insertion mutations are generally thought to be unresponsive to EGFR‐tyrosine kinase inhibitor (TKI) therapy. Presented here is a case of stage IV NSCLC harboring an uncommon EGFR exon 20 insertion mutation that was maintained at minimal progressive disease for 54 months, with 36 months on the second‐generation TKI afatinib. Contrary to the existing literature, the patient in this case demonstrated a long, durable response to the EGFR‐TKI, which was exhibited by a long survival endpoint. This suggest...
Source: Asia-Pacific Journal of Clinical Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Raymond Tsz ‐Tong Chan Tags: SUPPLEMENT ARTICLE Source Type: research

Case sharing of a patient re ‐challenged with afatinib for EGFR‐mutated advanced non–small cell lung cancer
Abstract A 65‐year‐old female with diabetes mellitus but otherwise good health in the past suffered from cough with occasional blood‐stained sputum during initial presentation. The patient was diagnosed with pulmonary poorly differentiated adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 19 deletion and hence received afatinib therapy for 25 months without obvious adverse events except for a grade 1–2 acneiform rash. The disease was stabilized after subsequent cycles of chemotherapy with pemetrexed and carboplatin followed by maintenance pemetrexed. The patient was rechallenged with afatinib trea...
Source: Asia-Pacific Journal of Clinical Oncology - March 6, 2018 Category: Cancer & Oncology Authors: Victor H.F. Lee Tags: SUPPLEMENT ARTICLE Source Type: research